JPWO2020005877A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020005877A5
JPWO2020005877A5 JP2020572894A JP2020572894A JPWO2020005877A5 JP WO2020005877 A5 JPWO2020005877 A5 JP WO2020005877A5 JP 2020572894 A JP2020572894 A JP 2020572894A JP 2020572894 A JP2020572894 A JP 2020572894A JP WO2020005877 A5 JPWO2020005877 A5 JP WO2020005877A5
Authority
JP
Japan
Prior art keywords
methyl
thiazolo
benzothiazole
fluoro
indazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020572894A
Other languages
English (en)
Japanese (ja)
Other versions
JP7515415B2 (ja
JP2021528466A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/038895 external-priority patent/WO2020005877A1/en
Publication of JP2021528466A publication Critical patent/JP2021528466A/ja
Publication of JPWO2020005877A5 publication Critical patent/JPWO2020005877A5/ja
Application granted granted Critical
Publication of JP7515415B2 publication Critical patent/JP7515415B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020572894A 2018-06-27 2019-06-25 ハンチントン病を処置するためのヘテロアリール化合物 Active JP7515415B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690540P 2018-06-27 2018-06-27
US62/690,540 2018-06-27
PCT/US2019/038895 WO2020005877A1 (en) 2018-06-27 2019-06-25 Heteroaryl compounds for treating huntington's disease

Publications (3)

Publication Number Publication Date
JP2021528466A JP2021528466A (ja) 2021-10-21
JPWO2020005877A5 true JPWO2020005877A5 (ru) 2022-06-21
JP7515415B2 JP7515415B2 (ja) 2024-07-12

Family

ID=67185796

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020572894A Active JP7515415B2 (ja) 2018-06-27 2019-06-25 ハンチントン病を処置するためのヘテロアリール化合物

Country Status (13)

Country Link
US (1) US20210284660A1 (ru)
EP (1) EP3814345A1 (ru)
JP (1) JP7515415B2 (ru)
KR (1) KR20210038845A (ru)
CN (1) CN112805280A (ru)
AU (2) AU2019294482B2 (ru)
BR (1) BR112020026534A2 (ru)
CA (1) CA3104516A1 (ru)
EA (1) EA202092899A1 (ru)
IL (1) IL279714A (ru)
MX (1) MX2020014315A (ru)
SG (1) SG11202012869SA (ru)
WO (1) WO2020005877A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113717154A (zh) 2015-12-10 2021-11-30 Ptc医疗公司 用于治疗亨廷顿病的方法
WO2018226622A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20210005559A (ko) 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CA3103976A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113677344A (zh) 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
CA3156848A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
WO2021222366A1 (en) * 2020-04-28 2021-11-04 Kymera Therapeutics, Inc. Irak inhibitors and uses thereof
CN116997548A (zh) 2020-05-13 2023-11-03 Chdi基金会股份有限公司 用于治疗亨廷顿病的htt调节剂
US20240239811A1 (en) 2020-07-02 2024-07-18 Remix Therapeutics Inc. 5-(5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the t
MX2023000168A (es) 2020-07-02 2023-04-20 Remix Therapeutics Inc Derivados de 2-(indazol-5-il)-6-(piperidin-4-il)-1,7-naftiridina y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas.
WO2022194800A1 (en) * 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thienopyrimidinone derivatives
CN116981673A (zh) * 2021-03-17 2023-10-31 豪夫迈·罗氏有限公司 新颖噻二唑并嘧啶酮衍生物
IL305203A (en) * 2021-03-17 2023-10-01 Hoffmann La Roche New histories of thiazolopyrimidines
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
CN116262758A (zh) * 2021-12-15 2023-06-16 上海博悦生物科技有限公司 7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
WO2023225244A1 (en) * 2022-05-20 2023-11-23 Biogen Ma Inc. Heterocyclic compounds for treating huntington's disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423133B2 (en) 2002-08-23 2008-09-09 The Board Of Trustees Of The Leland Stanford Junior University Fluorescent glycosides and methods for their use
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
AU2007229492B2 (en) * 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US20090258907A1 (en) * 2008-04-09 2009-10-15 Abbott Laboratories Compounds useful as inhibitors of rock kinases
WO2010024903A1 (en) 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
WO2010071819A1 (en) * 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
EA201270778A1 (ru) * 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
US20130046093A1 (en) 2011-08-18 2013-02-21 Korea Institute Of Science And Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
EP3227301A1 (de) 2014-12-02 2017-10-11 Bayer CropScience AG Bicyclische verbindungen als schädlingsbekämpfungsmittel
WO2016144351A1 (en) 2015-03-11 2016-09-15 E. I. Du Pont De Nemours And Company Heterocycle-substituted bicyclic azole pesticides
CN113717154A (zh) 2015-12-10 2021-11-30 Ptc医疗公司 用于治疗亨廷顿病的方法
CA3015947A1 (en) * 2016-03-11 2017-09-14 Ac Immune Sa Bicyclic compounds for diagnosis and therapy of alpha-synuclein associated disorders
US10526345B2 (en) * 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds

Similar Documents

Publication Publication Date Title
JPWO2020005877A5 (ru)
JP7399869B2 (ja) ハンチントン病を処置するための化合物
JP2020522570A5 (ru)
AU2019203444B2 (en) Bicyclic lactams and methods of use thereof
JPWO2019191229A5 (ru)
JPWO2020005873A5 (ru)
JPWO2019191092A5 (ru)
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2021503004A5 (ru)
JP2015504057A5 (ru)
AU2020277027A1 (en) Compounds for treating huntington's disease
CN112805280A (zh) 用于治疗亨廷顿氏病的杂芳基化合物
JP2014506929A5 (ru)
EP3814360A1 (en) Heteroaryl compounds for treating huntington's disease
HRP20151232T1 (hr) Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
JP2011500774A5 (ru)
JP2015537010A5 (ru)
JP2015508075A5 (ru)
JP2011511034A5 (ru)
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
HUE032770T2 (en) New NK-3 receptor selective antagonist compounds, pharmaceutical compositions and methods for use in NK-3 receptor mediated disorders
JP2021506941A5 (ru)
CA2649521A1 (en) Novel piperazine compound, and use thereof as hcv polymerase inhibitor
IL297044A (en) Compounds for the treatment of Huntington's disease